Abstract
Background Pretreatment health-related quality of life (HRQOL) is associated with survival outcome in lung cancer patients. There is a lack of systematic research on pretreatment HRQOL in lung cancer patients who receive integrative oncology (IO). We evaluated patient-reported outcomes in these patients at time of diagnosis at a certified oncology and lung cancer centre. Methods The present analysis is a prospective real-world data study. Clinical and demographic data were obtained from the accredited Network Oncology cancer registry. Pretreatment HRQOL was evaluated (international standardized questionnaires) for people with all-stage lung cancer at first diagnosis that received IO consisting of standard therapy and multimodal add-on complementary concepts. Univariate and adjusted multivariate regression analyses were performed with R. Results. Eighty seven patients with all-stage lung cancer were eligible for the questionnaire analysis (median age 68.0 years, IQR 59.0–74.4). Thirty percent of the total cohort reported financial difficulties. Self-reported pretreatment financial difficulty was associated with younger age (p=0.007), pretreatment pain (p=0.006), anxiety (p=0.04), and low mood (p=0.03). Pain (p=0.03) and young age (p=0.02) in the early- and late-stage lung cancer were associated with financial difficulties. Conclusion We suggest physicians screen lung cancer patients at working age (broadly aged ≤65 years) and/or who report increased pain at the time of diagnosis as they might be at particular risk for emotional, physical, and financial problems. Our results emphasize to address emotional and physical needs before and during early treatment in lung cancer patients as suggested in integrative and supportive cancer concepts.
Highlights
Lung cancer is the most common cancer worldwide (1.83 million estimated new cases, 12.9% of all cancers worldwide) and the most common cause of death from cancer worldwide [1]
Studies suggest that pretreatment health-related quality of life (HRQOL) in lung cancer patients is predictive for survival
We evaluated pretreatment HRQOL in lung cancer patients receiving treatments within integrative oncology (IO) concepts. irty percent of lung cancer patients report an increased financial burden at diagnosis independent of their tumor stage. is burden is associated with patient’s lower psychological and physical health
Summary
Lung cancer is the most common cancer worldwide (1.83 million estimated new cases, 12.9% of all cancers worldwide) and the most common cause of death from cancer worldwide (one cancer death in five, 1.59 million deaths, 19.4% of the total) [1]. According to the lung cancer alliance, only 17% of patients diagnosed with lung cancer survive for five years compared to 65% or 99% in colon or prostate cancer [2]. Pretreatment health-related quality of life (HRQOL) and its related parameters predict survival in lung cancer patients [5, 6]. Pretreatment HRQOL data seem to provide the most reliable information to establish prognostic criteria for the treatment of patients with cancer [8]. Compared to follow-up HRQOL evaluations, they are easier to assess and show disease-specific rather than treatment-specific characteristics [8]. Pretreatment health-related quality of life (HRQOL) is associated with survival outcome in lung cancer patients. Ere is a lack of systematic research on pretreatment HRQOL in lung cancer patients who receive integrative oncology (IO).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: Evidence-Based Complementary and Alternative Medicine
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.